Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2893867 | 0.89 | GRM4 (0.34) | GRM1GRM4KLKB1LMNASMN1; SMN2 | |
| SCHEMBL2889597 | 0.89 | KLKB1 (0.35) | GRM1GRM4KLKB1LMNASMN1; SMN2 | |
| SCHEMBL2891957 | 0.85 | GRM1 (0.41) | GRM1GRM4KLKB1LMNASMN1; SMN2 | |
| SCHEMBL2889604 | 0.83 | GRM1 (0.44) | GRM1GRM4LMNASMN1; SMN2GRM7 | |
| SCHEMBL2884250 | 0.82 | GRM4 (0.41) | GRM1GRM4KLKB1LMNASMN1; SMN2 | |
| SCHEMBL551114 | 0.82 | GRM1 (0.44) | GRM1GRM4LMNASMN1; SMN2CHRM5 | |
| SCHEMBL2889428 | 0.79 | GRM1 (0.41) | GRM1GRM4LMNASMN1; SMN2CHRM5 | |
| SCHEMBL2884263 | 0.79 | GRM1 (0.42) | GRM1GRM4LMNASMN1; SMN2CHRM5 | |
| SCHEMBL3327139 | 0.78 | GRM1 (0.40) | GRM1GRM4LMNASMN1; SMN2CHRM5 | |
| SCHEMBL2889967 | 0.76 | GRM1 (0.40) | GRM1GRM4LMNASMN1; SMN2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2010-05-27 | — | — | US | disclosed |
| US-7674807-B2 | Heterocycle-substituted n-phenyl-phthalamide derivatives, related compounds and their use as insecticides | BAYER CROPSCIENCE AG (DE) | 2010-03-09 | — | — | US | disclosed |
| EP-1727804-B1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2009-11-04 | — | — | EP | disclosed |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | BAYER CROPSCIENCE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1727804-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005095351-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | DDT, SQOR, CYP2S1 | GRM1 1638/4885GRM4 3253/4885KLKB1 4851/4885 |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | CHRM1, KCNH1, DDT | GRM1 1863/4885GRM4 3860/4885KLKB1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.